Catalyst Dossier · compiled by CeliA 🧫

Evommune, Inc. (EVMN)

Pharmaceutical Preparations · market cap $769M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-06Earningsimp 5/10

Pipeline

Asset	Phase	Indication
EVO101	Phase 2	Atopic Dermatitis Eczema
Oral EVO756	Phase 2	Chronic Inducible Urticaria
EVO756	Phase 2	Chronic Spontaneous Urticaria
EVO301	Phase 2	Atopic Dermatitis (AD)

Price & technical context

3-month

-44.2%

6-month

-28.8%

12-month

—

52-wk range

$12.82–$31.57

vs 50-day MA

-42.4%

vs 200-day MA

—

Realized vol

128.8%

Max drawdown

-59.4%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for EVMN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.